Adamis rises on promising lab data for COVID-19 treatment

DMK Pharmaceuticals

24/08/2021 17:06

** Shares of drug developer  ADMP.O  rise 2.3% to $1.1
    ** Co says data from a study which tested effects of its
experimental therapy, Tempol, on immune cells of COVID-19
patients shows the drug has strong in-vitro anti-cytokine
activity  urn:newsml:reuters.com:*:nGNX4ZnR3F
    ** Data from study, conducted at Human Immune Monitoring
Center at Stanford University, was published in peer reviewed
journal, Clinical Immunology
    ** In June, co said it has begun process to start clinical
trial of Tempol after National Institutes of Health identified
the drug as a potential antiviral for COVID-19  urn:newsml:reuters.com:*:nL3N2NT2V1
    ** Co has worldwide license to use Tempol to treat
respiratory diseases including asthma and influenza, among other
conditions

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))